Nippard rates the two drugs highly for supervised weight loss and notes that many popular peptide claims lack strong human evidence.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
On India Today, the two weighed the benefits of GLP-1 medicines against misuse, with concerns raised about cosmetic use for weight loss.
Diabetes.co.uk reports the late-stage result for Lilly's experimental drug in people with type 2 diabetes. Tap through for the trial details.
Loading…